- Home
- PMCB vs POAI Comparison
PMCB vs POAI Comparison
Compare PMCB & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- POAI
- Stock Information
- Founded
- PMCB 1996
- POAI 2002
- Country
- PMCB United States
- POAI United States
- Employees
- PMCB N/A
- POAI N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- POAI Industrial Specialties
- Sector
- PMCB Health Care
- POAI Health Care
- Exchange
- PMCB Nasdaq
- POAI Nasdaq
- Market Cap
- PMCB 6.7M
- POAI 7.8M
- IPO Year
- PMCB N/A
- POAI N/A
- Fundamental
- Price
- PMCB $1.04
- POAI $14.77
- Analyst Decision
- PMCB
- POAI Hold
- Analyst Count
- PMCB 0
- POAI 1
- Target Price
- PMCB N/A
- POAI N/A
- AVG Volume (30 Days)
- PMCB 121.2K
- POAI 230.9K
- Earning Date
- PMCB 09-15-2025
- POAI 11-11-2025
- Dividend Yield
- PMCB N/A
- POAI N/A
- EPS Growth
- PMCB N/A
- POAI N/A
- EPS
- PMCB 0.01
- POAI N/A
- Revenue
- PMCB N/A
- POAI $1,664,696.00
- Revenue This Year
- PMCB N/A
- POAI $486.27
- Revenue Next Year
- PMCB N/A
- POAI $65.50
- P/E Ratio
- PMCB $163.65
- POAI N/A
- Revenue Growth
- PMCB N/A
- POAI 71.65
- 52 Week Low
- PMCB $0.80
- POAI $8.25
- 52 Week High
- PMCB $2.42
- POAI $45.90
- Technical
- Relative Strength Index (RSI)
- PMCB 52.01
- POAI 78.34
- Support Level
- PMCB $0.94
- POAI $12.15
- Resistance Level
- PMCB $1.06
- POAI $15.15
- Average True Range (ATR)
- PMCB 0.08
- POAI 1.98
- MACD
- PMCB 0.00
- POAI 1.19
- Stochastic Oscillator
- PMCB 38.16
- POAI 45.66
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.